rezatapopt + azacitidine

About PMV Pharma

PMV Pharma's mission is to conquer cancer by restoring the function of the most frequently mutated tumor suppressor, p53. The company's key achievement is advancing rezatapopt, a first-in-class p53 Y220C reactivator, into a pivotal Phase 1/2 trial (PYNNACLE) with Fast Track designation and publishing compelling first-in-human data in the New England Journal of Medicine. Its strategy leverages a deep structural biology platform to develop tumor-agnostic therapies targeting specific p53 hotspot mutations, aiming to address a major unmet need in approximately 50% of all cancers.

About PMV Pharmaceuticals

PMV Pharmaceuticals' mission is to conquer cancer by correcting the function of mutant p53, the most frequently altered tumor suppressor in human oncology. The company's core achievement is advancing rezatapopt (PC14586), a first-in-class p53 Y220C reactivator, into the pivotal PYNNACLE Phase 1/2 study, with data recently published in the New England Journal of Medicine demonstrating proof-of-concept. Its strategy integrates a mutation-focused, tumor-agnostic development path with a deep pipeline targeting additional p53 hotspot mutations, aiming to establish a new class of precision oncology therapeutics. PMV operates as a publicly traded entity, building upon over four decades of foundational p53 research co-discovered by its scientific founder.

Therapeutic Areas